Allogene Therapeutics (ALLO) Operating Expenses (2018 - 2026)
Allogene Therapeutics (ALLO) posted Operating Expenses of $46.1 million for Q1 2026, up 8.7% sequentially from $42.4 million in Q4 2025, and down 29.3% YoY from $65.2 million in Q1 2025.
Allogene Therapeutics (ALLO) Operating Expenses (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Operating Expenses for 9 years, with the latest figure at $46.1 million in Q1 2026.
- Quarterly Operating Expenses fell 29.3% year-over-year to $46.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $190.2 million (down 29.26% YoY) and the FY2025 annual result came in at $209.3 million, down 23.39% from the prior year.
- Operating Expenses grew to $46.1 million in Q1 2026 per ALLO's latest filing, from $42.4 million in the prior quarter.
- Over five years, Operating Expenses peaked at $99.1 million in Q1 2023 and troughed at $42.4 million in Q4 2025.
- A 5-year average of $70.1 million and a median of $71.4 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses surged 30.4% in 2022, then sank 37.44% in 2025.
- Over 5 years, Operating Expenses stood at $96.4 million in 2022, then retreated by 11.71% to $85.1 million in 2023, then fell by 28.94% to $60.5 million in 2024, then retreated by 29.9% to $42.4 million in 2025, then rose by 8.7% to $46.1 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $46.1 million, $42.4 million, and $44.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | 51.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.56 Mn |
| Mar 31, 2026 | 46.09 Mn |
| Dec 31, 2025 | 42.40 Mn |
| Sep 30, 2025 | 44.90 Mn |
| Jun 30, 2025 | 56.82 Mn |
| Mar 31, 2025 | 65.19 Mn |
| Dec 31, 2024 | 60.49 Mn |
| Sep 30, 2024 | 71.77 Mn |
| Jun 30, 2024 | 71.43 Mn |
| Mar 31, 2024 | 69.53 Mn |
| Dec 31, 2023 | 85.13 Mn |
| Sep 30, 2023 | 63.02 Mn |
| Jun 30, 2023 | 80.56 Mn |
| Mar 31, 2023 | 99.12 Mn |
| Dec 31, 2022 | 96.42 Mn |
| Sep 30, 2022 | 82.54 Mn |
| Jun 30, 2022 | 76.68 Mn |
| Mar 31, 2022 | 80.05 Mn |
| Dec 31, 2021 | 73.94 Mn |
| Sep 30, 2021 | 77.72 Mn |